Cancer antigen 125 (CA-125)


Tuxen MK, Sölétormos G, Petersen PH and Dombernowsky P, 2001, Clin Chem Lab Med, 39, 531-8 , Interpretation of sequential measurements of cancer Antigen 125 (CA 125), Carcinoembryonic Antigen (CEA) and Tissue Polypeptide Antigen (TPA) based on analytical imprecision and biological variation in the monitoring of ovarian cancer


Total Score


Parameter Score
1. Scale A
2. Study Population A
3. Samples A
4. Measurand A
5. Pre-Analytical A
6. Replicate Analysis B
7. Steady State A
8. Outlier Analysis C
9. Normality A
10. Variance Homogeneity A
12. CI A
13. No of Results C
14. Concentrations A
15. Total Score C8,13

Item Details

Parameter Score
Matrix Serum
Measurand Cancer antigen 125 (CA-125)
Unit U / L
Overall Analytical Principle Method Immunoassay; RIA
Number of Subjects 31
Number of Subjects included in BV estimation 31
Ethinicity Caucasian
Age Mean / Median 55.0
Age Min 32.0
Age Max 71.0
Age SD
Number of Males
Number of Females 31
State of Well Being
Healthy (excl pregnant)
Study Duration Length 1
Study Duration Units Year
Sampling Intervals, e.g. X sample(s) per Interval Unit
Interval Units Week
Sampling Times Start Time:
End Time:
Number of Samples 16
Average Number of Samples Used for BV Estimation 16.0
Average Number of Replicates 2.0
Estimates of CVi 20.0
Calculated Confidence Intervals of CVi Lower: 18.69, Upper: 21.48
Estimates of CVg
Calculated Confidence Intervals of CVg Lower: , Upper:
Analytical CV 7.8
Calculated Confidence Intervals of Analytical CV Lower: 7.34, Upper: 8.32
Measurand Mean 0.8
Measurand Min
Measurand Max
Measurand SD